Transitions of blood immune endotypes and improved outcome by anakinra in COVID-19 pneumonia: an analysis of the SAVE-MORE randomized controlled trial.
Anakinra
COVID-19
Endotypes
Viral sepsis
Journal
Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902
Informations de publication
Date de publication:
12 Mar 2024
12 Mar 2024
Historique:
received:
11
01
2024
accepted:
27
02
2024
medline:
13
3
2024
pubmed:
13
3
2024
entrez:
13
3
2024
Statut:
epublish
Résumé
Endotype classification may guide immunomodulatory management of patients with bacterial and viral sepsis. We aimed to identify immune endotypes and transitions associated with response to anakinra (human interleukin 1 receptor antagonist) in participants in the SAVE-MORE trial. Adult patients hospitalized with radiological findings of PCR-confirmed severe pneumonia caused by SARS-CoV-2 and plasma-soluble urokinase plasminogen activator receptor levels of ≥ 6 ng/ml in the SAVE-MORE trial (NCT04680949) were characterized at baseline and days 4 and 7 of treatment using a previously defined 33-messenger RNA classifier to assign an immunological endotype in blood. Endpoints were changes in endotypes and progression to severe respiratory failure (SRF) associated with anakinra treatment. At baseline, 23.2% of 393 patients were designated as inflammopathic, 41.1% as adaptive, and 35.7% as coagulopathic. Only 23.9% were designated as the same endotype at days 4 and 7 compared to baseline, while all other patients transitioned between endotypes. Anakinra-treated patients were more likely to remain in the adaptive endotype during 7-day treatment (24.4% vs. 9.9%; p < 0.001). Anakinra also protected patients with coagulopathic endotype at day 7 against SRF compared to placebo (27.8% vs. 55.9%; p = 0.013). We identify an association between endotypes defined using blood transcriptome and anakinra therapy for COVID-19 pneumonia, with anakinra-treated patients shifting toward endotypes associated with a better outcome, mainly the adaptive endotype. Trial registration ClinicalTrials.gov, NCT04680949, December 23, 2020.
Sections du résumé
BACKGROUND
BACKGROUND
Endotype classification may guide immunomodulatory management of patients with bacterial and viral sepsis. We aimed to identify immune endotypes and transitions associated with response to anakinra (human interleukin 1 receptor antagonist) in participants in the SAVE-MORE trial.
METHODS
METHODS
Adult patients hospitalized with radiological findings of PCR-confirmed severe pneumonia caused by SARS-CoV-2 and plasma-soluble urokinase plasminogen activator receptor levels of ≥ 6 ng/ml in the SAVE-MORE trial (NCT04680949) were characterized at baseline and days 4 and 7 of treatment using a previously defined 33-messenger RNA classifier to assign an immunological endotype in blood. Endpoints were changes in endotypes and progression to severe respiratory failure (SRF) associated with anakinra treatment.
RESULTS
RESULTS
At baseline, 23.2% of 393 patients were designated as inflammopathic, 41.1% as adaptive, and 35.7% as coagulopathic. Only 23.9% were designated as the same endotype at days 4 and 7 compared to baseline, while all other patients transitioned between endotypes. Anakinra-treated patients were more likely to remain in the adaptive endotype during 7-day treatment (24.4% vs. 9.9%; p < 0.001). Anakinra also protected patients with coagulopathic endotype at day 7 against SRF compared to placebo (27.8% vs. 55.9%; p = 0.013).
CONCLUSION
CONCLUSIONS
We identify an association between endotypes defined using blood transcriptome and anakinra therapy for COVID-19 pneumonia, with anakinra-treated patients shifting toward endotypes associated with a better outcome, mainly the adaptive endotype. Trial registration ClinicalTrials.gov, NCT04680949, December 23, 2020.
Identifiants
pubmed: 38475786
doi: 10.1186/s13054-024-04852-z
pii: 10.1186/s13054-024-04852-z
doi:
Banques de données
ClinicalTrials.gov
['NCT04680949']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
73Informations de copyright
© 2024. The Author(s).
Références
Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for sepsis and septic Shock (Sepsis-3). JAMA. 2016;315:801–10.
doi: 10.1001/jama.2016.0287
pubmed: 26903338
pmcid: 4968574
Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis 5 for the Global Burden of Disease Study. Lancet. 2020;395:200–11.
doi: 10.1016/S0140-6736(19)32989-7
pubmed: 31954465
pmcid: 6970225
World Health Organization. Coronavirus disease (COVID-19) pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019?gclid=Cj0KCQiAhs79BRD0ARIsAC6XpaXhxHeN64r7-j5rvv0ZDtNGxNkA0e2EWCAUr8QWWj-qi_PPrXOljroaAjXBEALw_wcB .
Giamarellos-Bourboulis EJ, Netea MG, Rovina N, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2020;27:992-1000.e3.
doi: 10.1016/j.chom.2020.04.009
pubmed: 32320677
pmcid: 7172841
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62.
doi: 10.1016/S0140-6736(20)30566-3
pubmed: 32171076
pmcid: 7270627
Li H, Liu L, Zhang D, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet. 2020;395:1517–20.
doi: 10.1016/S0140-6736(20)30920-X
pubmed: 32311318
pmcid: 7164875
Karakike E, Giamarellos-Bourboulis EJ, Kyprianou M, et al. Coronavirus disease 2019 as cause of viral sepsis: a systematic review and meta-analysis. Crit Care Med. 2021;49:2042–57.
doi: 10.1097/CCM.0000000000005195
pubmed: 34259663
pmcid: 8594513
Maslove DM, Tang B, Shankar-Hari M, et al. Redefining critical illness. Nat Med. 2022;28:1141–8.
doi: 10.1038/s41591-022-01843-x
pubmed: 35715504
Kyriazopoulou E, Giamarellos-Bourboulis EJ. Monitoring immunomodulation in patients with sepsis. Expert Rev Mol Diagn. 2021;21:17–29.
doi: 10.1080/14737159.2020.1851199
pubmed: 33183116
Sweeney TE, Azad TD, Donato M, et al. Unsupervised analysis of transcriptomics in bacterial sepsis across multiple datasets reveals three robust clusters. Crit Care Med. 2018;46:915–25.
doi: 10.1097/CCM.0000000000003084
pubmed: 29537985
pmcid: 5953807
Sweeney TE, Liesenfeld O, Wacker J, et al. Validation of inflammopathic, adaptive, and coagulopathic sepsis endotypes in coronavirus disease 2019. Crit Care Med. 2021;49:e170–8.
doi: 10.1097/CCM.0000000000004786
pubmed: 33201004
Kyriazopoulou E, Poulakou G, Milionis H, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med. 2021;27:1752–60.
doi: 10.1038/s41591-021-01499-z
pubmed: 34480127
pmcid: 8516650
European Medicines Agency. EMA recommends approval for use of Kineret in adults with COVID-19. 2021. https://www.ema.europa.eu/en/news/ema-recommends-approval-use-kineret-adults-covid-19 .
Fact sheet for healthcare providers: emergency use authorization for kineret https://www.fda.gov/media/163075/download .
World Health Organization. Clinical management of COVID-19: living guideline, 13 January 2023. https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2023.1 .
Akinosoglou K, Kotsaki A, Gounaridi IM, et al. Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: a subgroup analysis of the SAVE-MORE randomised trial. eClinicalMedicine. 2023;56:101785.
doi: 10.1016/j.eclinm.2022.101785
pubmed: 36590789
Thair SA, He YD, Hasin-Brumshtein Y, et al. Transcriptomic similarities and differences in host response between SARS-CoV-2 and other viral infections. iScience. 2020;24:101947.
doi: 10.1016/j.isci.2020.101947
pubmed: 33437935
pmcid: 7786129
Davenport EE, Burnham KL, Radhakrishnan J, et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir Med. 2016;4:259–71.
doi: 10.1016/S2213-2600(16)00046-1
pubmed: 26917434
pmcid: 4820667
Scicluna BP, van Vught LA, Zwinderman AH, et al. Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study. Lancet Respir Med. 2017;5:816–26.
doi: 10.1016/S2213-2600(17)30294-1
pubmed: 28864056
Iglesias J, Vassallo AV, Liesenfeld O, et al. A 33-mRNA classifier is able to produce inflammopathic, adaptive, and coagulopathic endotypes with prognostic significance: the outcomes of metabolic resuscitation using ascorbic acid, thiamine, and glucocorticoids in the early treatment of sepsis (ORANGES) trial. J Pers Med. 2020;11:9.
doi: 10.3390/jpm11010009
pubmed: 33374697
pmcid: 7822486